United States Chronic Obstructive Pulmonary Disease (COPD) Drugs Market is expected to reach US$ 7.8 billion by 2032 | Top key players - AstraZeneca, Pfizer Inc., Gsk Plc.

Market Size and Growth:

The Global Chronic Obstructive Pulmonary Disease Drugs Market Size reached US$ 24.67 billion in 2024 and is expected to reach US$ 35.15 billion by 2032, growing at a CAGR of 4.9% during the forecast period 2025-2032. The Market growth is driven by the rising prevalence of COPD due to increasing smoking rates and air pollution, along with advancements in inhalation therapies and drug formulations. According to DataM Intelligence

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-drugs-market?sz

The Chronic Obstructive Pulmonary Disease (COPD) Drugs Market refers to the industry focused on developing, producing, and distributing medications that manage and treat COPD, a progressive lung disorder causing airflow limitation. These drugs include bronchodilators, corticosteroids, phosphodiesterase-4 inhibitors, and combination therapies aimed at reducing symptoms, preventing exacerbations, and improving patients' respiratory function and quality of life.

Industry Recent Developments: United States

✅ November 2025: The market saw further innovation in inhaler therapies, such as novel once-daily triple combination inhalers, which aim to improve medication adherence and patient outcomes among individuals with moderate-to-severe COPD.

✅ October 2025: Demand for biologics and precision therapies increased as more clinicians adopted targeted treatment protocols for COPD patients, supported by updated clinical practice guidelines and the introduction of new biologic products for patients with high-risk or poorly controlled disease.

✅ September 2025: Companies accelerated R&D for long-acting bronchodilators and selective drugs, with major pharmaceutical firms expanding investment in pipeline therapies and mergers and acquisitions to strengthen the distribution and innovation for the COPD drug market.

Industry Recent Developments: Japan

✅ November 2025: There was a significant shift toward advanced, digitally integrated inhaler devices tailored for COPD management, with patient-centric designs and smart medication adherence features supporting older population cohorts with chronic respiratory disease.

✅ October 2025: The launch and wider adoption of fixed-dose combination therapies-including inhaled corticosteroids, LABAs, and LAMAs-offered improved management and streamlined regimens for COPD patients, driving increased use among healthcare providers.

✅ September 2025: Advances in biologic and targeted therapies for COPD, alongside regulatory initiatives promoting rapid access to new drugs and support for innovative clinical trials, contributed to heightened therapeutic options and enhanced disease management for complex or severe cases.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-drugs-market?sz

Key FDA Approvals (2025):

✅ GSK - Nucala® (mepolizumab): FDA approval granted in May 2025 for use as an add-on maintenance treatment for adults with inadequately controlled COPD with an eosinophilic phenotype. (GSK press release + FDA label).

✅ Context note: biologic/add-on approvals (Dupixent/dupilumab) and first-in-class inhaled agents approved in 2024 changed the competitive baseline going into 2025 (see timeline below).

Major Mergers & Acquisitions (2025):

✅ Merck (MSD) - announced acquisition of Verona Pharma (July 9, 2025) for ~$10 billion, acquiring Verona's COPD asset Ohtuvayre (ensifentrine) and associated commercial rights. The deal (announced July 9, 2025) is a material industry event shifting ownership of a recently launched COPD medicine into a big-pharma commercial engine.

✅ Why this matters: Verona's Ohtuvayre had been approved and launched in the U.S. (June 2024 approval; commercial availability began August 2024). The Merck deal accelerates global rollout capabilities and commercial scale for that agent.

Regulatory Activity / filings in 2025:

✅ EMA - accepted GSK's mepolizumab (Nucala) indication-expansion filing for COPD for review (announcement March 24, 2025). This is the key EU regulatory pathway event for Nucala's COPD label.

✅ India (CDSCO committee) - pulmonary committee documentation (11 June 2025 meeting) shows regulator review activity around umeclidinium inhalation formulations and Phase-III waiver discussions - an indicator of ongoing product-level regulatory activity in India for LAMA/LABA/FDC inhalers. (committee minutes / recommendation file).

Major Key Players:

Boehringer Ingelheim Pharmaceuticals, Inc.
Gsk Plc
Viatris Inc. (Mylan N.V.)
Lupin Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Organon Group of companies
Pfizer Inc.
Covis Pharma GmbH.

Segments Covered in the Chronic Obstructive Pulmonary Disease Drugs Market:

By Drug Class: Bronchodilators, Beclomethasone, Combination Inhaled Medicines, Phosphodiesterase Inhibitor (Roflumilast), Antibiotics, Others.

By Route of Administration: Inhalation, Oral, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Chronic Obstructive Pulmonary Disease Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-drugs-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Chronic Obstructive Pulmonary Disease Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Chronic Obstructive Pulmonary Disease Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Chronic Obstructive Pulmonary Disease Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Chronic Obstructive Pulmonary Disease Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Chronic Obstructive Pulmonary Disease Drugs market?

➠ Who are the global key manufacturers of the Chronic Obstructive Pulmonary Disease Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Chronic Obstructive Pulmonary Disease Drugs market opportunities and threats faced by the vendors in the global Chronic Obstructive Pulmonary Disease Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Chronic Obstructive Pulmonary Disease Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.